research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Janus Kinase Inhibitor Increases Hair Growth by Increasing Beta-Catenin Activity in Outer Root Sheath Cells
JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research Selective Janus Kinase 1 Inhibition Resolves Inflammation and Restores Hair Growth Offering a Viable Treatment Option for Alopecia Areata
Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Personalized Medicine in the Field of Inflammatory Skin Disorders
Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
research The Changing Landscape of Managing Hair Loss: A 30-Year Perspective
There have been major advances in diagnosing and treating hair loss over the last 30 years, with new drugs and improved hair transplant techniques.
research Hair Regrowth in a Patient With Central Centrifugal Cicatricial Alopecia After a 2-Month Trial of Baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib treatment for hair loss may worsen acne.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib, a hair regrowth treatment, may worsen acne.
research Pathomechanisms of Immune-Mediated Alopecia
The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis
JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
research Scarring Hair Follicle Destruction Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research New Treatments for Hair Loss
Several new treatments for different types of hair loss show promise in improving patient quality of life.
research Response of Alopecia Areata of the Beard to Oral Tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Immune Cell Regulation of the Hair Cycle
Immune cells affect hair growth and could lead to new hair loss treatments.
research Alopecia Areata and Alopecia Areata Incognita
Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
research A Retrospective Review of Pediatric Alopecia Areata Cases Seen in a Tertiary Institution in Singapore
Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research Baricitinib (Olumiant) for Severe Alopecia Areata Treatment Recommendations
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Response to Tofacitinib Therapy of Eyebrows and Eyelashes in Alopecia Areata
Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.